Citations

Clear

904 citation(s) found for "Gordon, S".

Segregation of functional networks is associated with cognitive resilience in Alzheimer’s disease
Ewers, Michael , Luan, Ying , Frontzkowski, Lukas , Rubinski, Anna , Dichgans, Martin , Hassenstab, Jason , Gordon, Brian A. , Chhatwal, Jasmeer P. , Xiong, Chengjie , Morris, John C. , Goate, Alison , Fagan, Anne M. , Berman, Sarah , Chui, Helena C., Cruchaga, Carlos , Farlow, Marty, Graff‐Radford, Neill R. , Martins, Ralph N. , Mori, Hiroshi , Perrin, Richard J. , Xiong, Chengjie , Fox, Nick C. , O’Connor, Antoinette , Salloway, Stephen , Danek, Adrian , Büerger, Katharina , Bateman, Randall J. , Habeck, Christian , Network, for the Alzheimer’s Disease Neuroimaging Initiative and the Dominantly Inherited Alzheimer, Vöglein, Jonathan , Gordon, Brian A , O'Connor, Antoinette , Stern, Yaakov , Franzmeier, Nicolai , Dichgans, Martin , Cruchaga, Carlos , Bateman, Randall J , Vöglein, Jonathan , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Berman, Sarah , Neitzel, Julia , Schofield, Peter R. , Benzinger, Tammie L.S. , Karch, Celeste M. , McDade, Eric , Allegri, Ricardo , Chui, Helena C. , Jucker, Mathias , Lee, Jae‐Hong , Rossor, Martin N. , Stern, Yaakov , Franzmeier, Nicolai , Network, for the Alzheimer’s Disease Neuroimaging Initiative and the Dominantly Inherited Alzheimer

Mayo Clinic

Brain | March 12, 2021 | Volume: 144 | Issue: 7 | Pages: 2176-2185

10.1093/brain/awab112 | PMID 33725114 Get It

Abstract Cognitive resilience is an important modulating factor of cognitive decline in Alzheimer’s disease, but the functional brain mechanisms that support cognitive resilience remain elusive. Given previous findings in normal ageing, we tested the hypothesis that higher segregation of the brain’s connectome into distinct functional networks represents a functional mechanism underlying cognitive resilience in Alzheimer’s disease. Using resting-state functional MRI, we assessed both resting-state functional MRI global system segregation, i.e. the balance of between-network to within-network connectivity, and the alternate index of modularity Q as predictors of cognitive resilience. We performed all analyses in two independent samples for validation: (i) 108 individuals with autosomal dominantly inherited Alzheimer’s disease and 71 non-carrier controls; and (ii) 156 amyloid-PET-positive subjects across the spectrum of sporadic Alzheimer’s disease and 184 amyloid-negative controls. In the autosomal dominant Alzheimer’s disease sample, disease severity was assessed by estimated years from symptom onset. In the sporadic Alzheimer’s sample, disease stage was assessed by temporal lobe tau-PET (i.e. composite across Braak stage I and III regions). In both samples, we tested whether the effect of disease severity on cognition was attenuated at higher levels of functional network segregation. For autosomal dominant Alzheimer’s disease, we found higher functional MRI-assessed system segregation to be associated with an attenuated effect of estimated years from symptom onset on global cognition (P = 0.007). Similarly, for patients with sporadic Alzheimer’s disease, higher functional MRI-assessed system segregation was associated with less decrement in global cognition (P = 0.001) and episodic memory (P = 0.004) per unit increase of temporal lobe tau-PET. Confirmatory analyses using the alternate index of modularity Q revealed consistent results. In conclusion, higher segregation of functional connections into distinct large-scale networks supports cognitive resilience in Alzheimer’s disease.
A large-scale multi-ethnic genome-wide association study of coronary artery disease
Tcheandjieu, Catherine , Zhu, Xiang , Clarke, Shoa L. , Lee, Kyung Min , Chen, Fei , Pyarajan, Saiju , Song, Rebecca J. , Plomondon, Mary E. , Waldo, Stephen W. , Sinnott-Armstrong, Nasa , Wojcik, Genevieve L. , Haessler, Jeffrey, Do, Ron , North, Kari, Haiman, Christopher, Bis, Joshua, Shen, Botong, Lange, Leslie A., Lu, Yingchang , Stanaway, Ian B. , Hebbring, Scott J. , Namjou, Bahram , Kaufman, Kenneth M. , Kamatani, Yoichiro, Ritchie, Marylyn D. , Baras, Aris , Natarajan, Pradeep , Raghavan, Sridharan , Lee, Jennifer , Tang, Hua, Sun, Yan V. , O’Donnell, Christopher J. , Kathiresan, Sekar , Saleheen, Danish , Gaziano, J. Michael , Reaven, Peter D. , Cho, Kelly , Graff, Mariaelisa , Huang, Jie , Clarke, Shoa L , Do, Ron , Natarajan, Pradeep , Min Lee, Kyung , Assimes, Themistocles L. , Hilliard, Austin T. , Napolioni, Valerio , Ma, Shining , Fang, Huaying , Gorman, Bryan R. , Maddox, Thomas M , Ho, Yuk-Lam Anne , Buyske, Steven , Kooperberg, Charles , Loos, Ruth J. F. , Verbanck, Marie , Chaudhary, Kumardeep , Avery, Christy L. , Marchand, Loı̈c Le , Wilkens, Lynne R. , Leonard, Hampton L. , Giri, Ayush , Dikilitas, Ozan , Kullo, Iftikhar J. , Jarvik, Gail P. , Gordon, Adam, Koyama, Satoshi , Ito, Kaoru , Ishigaki, Kazuyoshi , Kamatani, Yoichiro, Tsao, Noah L. , Verma, Shefali S. , Kember, Rachel L. , Lotta, Luca Andrea , Levin, Michael G. , Hauser, Elizabeth R. , Miller, Donald Ray , Vujković, Marijana , Huffman, Jennifer E. , Klarin, Derek , Voight, Benjamin F. , Rader, Daniel J , Chang, Kyong‐Mi , Damrauer, Scott M , Lynch, Julie A. , Wilson, Peter W.F. , Tsao, Philip S. , Bick, Alexander G.

Mayo Clinic

No container title available | March 10, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-275591/v1 Get It

Abstract Coronary artery disease (CAD) is a leading cause of death, yet its genetic determinants are not fully elucidated. We report a multi-ethnic genome-wide association study of CAD involving nearly a quarter of a million cases, incorporating the largest cohorts to date of Whites, Blacks, and Hispanics from the Million Veteran Program with existing studies including CARDIoGRAMplusC4D, UK Biobank, and Biobank Japan. We verify substantial and nearly equivalent heritability of CAD across multiple ancestral groups, discover 107 novel loci including the first nine on the X-chromosome, identify the first eight genome-wide significant loci among Blacks and Hispanics, and demonstrate that two common haplotypes are largely responsible for the risk stratification at the well-known 9p21 locus in most populations except those of African origin where both haplotypes are virtually absent. We identify 15 loci for angiographically derived burden of coronary atherosclerosis, which robustly overlap with the strongest and earliest loci reported to date for clinical CAD. Phenome-wide association analyses of novel loci and externally validated polygenic risk scores (PRS) augment signals from the insulin resistance cluster of risk factors and consequences, extend previously established pleiotropic associations of loci with traditional risk factors to include smoking and family history, and confirm a substantially reduced transferability of existing PRS to Blacks. Downstream integrative genomic analyses reinforce the critical role of endothelial, fibroblast, and smooth muscle cells within the coronary vessel wall in CAD susceptibility. Our study highlights the value of a multi-ethnic design in efficiently characterizing the genetic architecture of CAD across all human populations.
Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy
Jing, Ying , Zhang, Yongchang , Li, Kunyan , Chen, Xue , Heng, Jianfu, Gao, Qian , Ye, Youqiong , Zhang, Zhao , Liu, Yaoming , Lou, Yanyan , Diao, Lixia , Han, Leng , Ye, Youqiong , Zhang, Zhao , Lin, Steven H , Han, Leng , Wang, Jing , Lin, Steven H. , Liu, Hong , Chen, Xiang , Mills, Gordon B.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 8, 2021 | Volume: 113 | Issue: 10 | Pages: 1396-1404

10.1093/jnci/djab035 | PMID 33705549 Get It

Abstract Background Accumulated evidence supports the existence of sex-associated differences in immune systems. Understanding the role of sex in immune-related adverse events (irAEs) is important for management of irAE in patients receiving immunotherapy. Methods We performed meta-analysis on published clinical study data and multivariable logistic regression on pharmacovigilance data and applied a propensity algorithm to The Cancer Genome Atlas omics data. We further validated our observations in 2 independent in-house cohorts of 179 and 767 cancer patients treated with immune checkpoint inhibitors. Results A meta-analysis using 13 clinical studies that reported on 1096 female patients (36.8%, 95% confidence interval [CI] = 35.0% to 38.5%) and 1886 male patients (63.2%, 95% CI = 61.5% to 65.0%) demonstrated no statistically significant irAE risk difference between the sexes (odds ratio [OR] = 1.19, 95% CI = 0.91 to 1.54, 2-sided P = .21). Multivariable logistic regression analysis of 12 225 patients from the Food and drug administration Adverse Event Reporting System (FAERS) and 10 979 patients from VigiBase showed no statistically significant difference in irAEs by sex. A propensity score algorithm used on multi-omics data for 6019 patients from The Cancer Genome Atlas found no statistically significant difference by sex for irAE-related factors or pathways. The retrospective analysis of 2 in-house patient cohorts validated these results (OR = 1.55, 95% CI = 0.98 to 2.47, false discovery rate = 0.13, for cohort 1; OR = 1.16, 95% CI = 0.86 to 1.57, false discovery rate = 0.39, for cohort 2). Conclusions We observed minimal sex-associated differences in irAEs among cancer patients who received immune checkpoint inhibitor therapy. It may be unnecessary to consider sex effects for irAE management in clinical practice.
The Second NINDS/NIBIB Consensus Meeting to Define Neuropathological Criteria for the Diagnosis of Chronic Traumatic Encephalopathy
Bieniek, Kevin F. , Cairns, Nigel J. , Crary, John F. , Folkerth, Rebecca D., Keene, C. Dirk , Perl, Daniel P. , Stein, Thor D. , Vonsattel, Jean‐Paul, Stewart, William , Gordon, Wayne A., Alvarez, Victor E., Alosco, Michael L. , McKee, Ann C. , Babcock, Debra, Bellgowan, Patrick S.F. , Crane, Paul K. , Edlow, Brian L. , Huber, Bertrand R., Kiernan, Patrick T. , Dickson, Dennis W. , Litvan, Irene , Dams-O’Connor, Kristen , Tripodis, Yorghos , Mez, Jesse , Huber, Bertrand R. , Koroshetz, Walter J.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | February 21, 2021 | Volume: 80 | Issue: 3 | Pages: 210-219

10.1093/jnen/nlab001 | PMID 33611507 Get It

Abstract Chronic traumatic encephalopathy (CTE) is a neurodegenerative disorder associated with exposure to head trauma. In 2015, a panel of neuropathologists funded by the NINDS/NIBIB defined preliminary consensus neuropathological criteria for CTE, including the pathognomonic lesion of CTE as “an accumulation of abnormal hyperphosphorylated tau (p-tau) in neurons and astroglia distributed around small blood vessels at the depths of cortical sulci and in an irregular pattern,” based on review of 25 tauopathy cases. In 2016, the consensus panel met again to review and refine the preliminary criteria, with consideration around the minimum threshold for diagnosis and the reproducibility of a proposed pathological staging scheme. Eight neuropathologists evaluated 27 cases of tauopathies (17 CTE cases), blinded to clinical and demographic information. Generalized estimating equation analyses showed a statistically significant association between the raters and CTE diagnosis for both the blinded (OR = 72.11, 95% CI = 19.5–267.0) and unblinded rounds (OR = 256.91, 95% CI = 63.6–1558.6). Based on the challenges in assigning CTE stage, the panel proposed a working protocol including a minimum threshold for CTE diagnosis and an algorithm for the assessment of CTE severity as “Low CTE” or “High CTE” for use in future clinical, pathological, and molecular studies.
Dural augmentation approaches and complication rates after posterior fossa decompression for Chiari I malformation and syringomyelia: a Park-Reeves Syringomyelia Research Consortium study
Adelson, P. David , Akbari, S. Hassan A. , Albert, Gregory W. , Aldana, Philipp R. , Alden, Tord D. , Anderson, Richard C. E. , Bauer, David F. , Bethel-Anderson, Tammy, Brockmeyer, Douglas L. , Chern, Joshua J. , Couture, Daniel E., Durham, Susan, Ellenbogen, Richard G. , Eskandari, Ramin , George, Timothy M., Greene, Stephanie , Gross, Naina L. , Guillaume, Daniel, Hankinson, Todd C. , Heuer, Gregory G. , Iantosca, Mark, Iskandar, Bermans J. , Jackson, Eric M. , Keating, Robert F., Krieger, Mark D., Leonard, Jeffrey R. , Maher, Cormac O. , Mangano, Francesco T. , McComb, J. Gordon , McEvoy, Sean D., Meehan, Thanda, O’Neill, Brent R., Olavarria, Greg, Ragheb, John , Shannon, Chevis N. , Smyth, Matthew D. , Stone, Scellig , Strahle, Jennifer M. , Torner, James C., Tuite, Gerald F. , Wait, Scott D. , Wellons, John C. , Whitehead, William E. , Park, Tae Sung, Limbrick, David D. , Torner, James C. , Yahanda, Alexander T. , Daniels, David J. , Dlouhy, Brian J , Grant, Gerald A. , Graupman, Patrick C. , Greenfield, Jeffrey P. , Guillaume, Daniel J., Johnston, James M. , Menezes, Arnold H. , Selden, Nathan R. W. , Shah, Manish N. , Shimony, Joshua S. , Limbrick, David D.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | February 12, 2021 | Volume: 27 | Issue: 4 | Pages: 459-468

10.3171/2020.8.peds2087 | PMID 33578390 Get It

OBJECTIVE Posterior fossa decompression with duraplasty (PFDD) is commonly performed for Chiari I malformation (CM-I) with syringomyelia (SM). However, complication rates associated with various dural graft types are not well established. The objective of this study was to elucidate complication rates within 6 months of surgery among autograft and commonly used nonautologous grafts for pediatric patients who underwent PFDD for CM-I/SM. METHODS The Park-Reeves Syringomyelia Research Consortium database was queried for pediatric patients who had undergone PFDD for CM-I with SM. All patients had tonsillar ectopia ≥ 5 mm, syrinx diameter ≥ 3 mm, and ≥ 6 months of postoperative follow-up after PFDD. Complications (e.g., pseudomeningocele, CSF leak, meningitis, and hydrocephalus) and postoperative changes in syrinx size, headaches, and neck pain were compared for autograft versus nonautologous graft. RESULTS A total of 781 PFDD cases were analyzed (359 autograft, 422 nonautologous graft). Nonautologous grafts included bovine pericardium (n = 63), bovine collagen (n = 225), synthetic (n = 99), and human cadaveric allograft (n = 35). Autograft (103/359, 28.7%) had a similar overall complication rate compared to nonautologous graft (143/422, 33.9%) (p = 0.12). However, nonautologous graft was associated with significantly higher rates of pseudomeningocele (p = 0.04) and meningitis (p < 0.001). The higher rate of meningitis was influenced particularly by the higher rate of chemical meningitis (p = 0.002) versus infectious meningitis (p = 0.132). Among 4 types of nonautologous grafts, there were differences in complication rates (p = 0.02), including chemical meningitis (p = 0.01) and postoperative nausea/vomiting (p = 0.03). Allograft demonstrated the lowest complication rates overall (14.3%) and yielded significantly fewer complications compared to bovine collagen (p = 0.02) and synthetic (p = 0.003) grafts. Synthetic graft yielded higher complication rates than autograft (p = 0.01). Autograft and nonautologous graft resulted in equal improvements in syrinx size (p < 0.0001). No differences were found for postoperative changes in headaches or neck pain. CONCLUSIONS In the largest multicenter cohort to date, complication rates for dural autograft and nonautologous graft are similar after PFDD for CM-I/SM, although nonautologous graft results in higher rates of pseudomeningocele and meningitis. Rates of meningitis differ among nonautologous graft types. Autograft and nonautologous graft are equivalent for reducing syrinx size, headaches, and neck pain.
HER-2 Fluorescence In Situ Hybridization: Results From the Survey Program of the College of American Pathologists
Persons, Diane L., Tubbs, Raymond R., Cooley, Linda D. , Dewald, Gordon W., Dowling, Patricia K., Du, Emma, Mascarello, James T., Rao, Kathleen W., Wolff, Daynna J., Habegger-Vance, Gail, Wilson, Kathleen S.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 11, 2021 | Volume: 130 | Issue: 3 | Pages: 325-331

10.5858/2006-130-325-hfishr | PMID 16519559 Get It

Abstract Context. —Fluorescence in situ hybridization (FISH) is a common method used to determine HER-2 status in breast cancer. Limited information is available concerning reproducibility of FISH in determining HER-2 gene amplification. Objective. —To present proficiency testing results of FISH for HER-2 conducted by the Cytogenetics Resource Committee of the College of American Pathologists/American College of Medical Genetics. Design. —During the past 5 years, unstained sections from 9 invasive breast carcinomas were used for HER-2 FISH proficiency testing, allowing for comparison of FISH results among a large number of laboratories. Additional data were collected using an educational (ungraded) challenge and supplemental questions in the surveys. Results. —The number of laboratories participating in HER-2 FISH proficiency testing has increased steadily during the past 5 years (from 35 in 2000 to 139 in 2004). Reproducibility of test results among laboratories was excellent for breast tumors with low copy number (no HER-2 amplification) and for breast tumors with high copy number ( HER-2 amplification). However, there was considerable variation in interpretation of results for a tumor with low-level HER-2 amplification that was tested on 2 separate occasions. Responses to supplemental questions indicated that there was a need for consensus on the use of a separate equivocal/borderline interpretative category and the need for standardization of cutoff values used to define interpretative categories. Conclusions. —The College of American Pathologists proficiency survey programs provide useful information concerning the reproducibility of clinical testing for HER-2 by FISH and reflect clinical interpretation of HER-2 FISH analyses from laboratories across the country.
A Population-Based Study of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis in the United States from 2001-2015
Smith, Caleb J. , Ruan, Gordon , Thomas, John W., Tefferi, Ayalew , Goyal, Guarav, Go, Ronald S. , Shah, Meera

Mayo Clinic

Blood | February 8, 2021 | Volume: 136 | Issue: Supplement 1 | Pages: 48-48

10.1182/blood-2020-137611 Get It

Introduction: Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Primary Myelofibrosis (PMF) are BCR/ABL1-negative myeloproliferative neoplasms (MPN) that are associated with morbidity and increased mortality. Limited data regarding population-based outcomes for these MPNs have been reported. Our aim was to use the Surveillance, Epidemiology, and End Results (SEER) registry to investigate population based outcomes for PV, ET, and PMF. Methods: The SEER 18 registries were used to identify patients with ICD-O-3 diagnosis codes for PV (9950/3), ET (9962/3), and PMF (9961/3) from 2001-2015. For ET and PMF, histologic diagnosis was required for inclusion. Incidence was age-adjusted to the U.S. 2000 standard population. Causes of death were obtained and MPN-related death was defined as death from any myeloid disorder (ET, PV, PMF, acute myeloid leukemia [AML], acute monocytic leukemia, other myeloid/monocytic leukemia, and aleukemic, subleukemic and NOS). Relative survival (RS) was defined as the ratio of the proportion of observed survivors in a cohort of PV, ET, PMF patients to the proportion of expected survivors in a comparable set of individuals that did not respectively have PV, ET, or PMF, adjusting for the general survival of the US population for race, sex, age, and time when the diagnosis was established. Time to leukemic transformation was calculated using the left-truncated life tables session with a 3-month latency period used to prevent misattribution. Overall survival (OS) was calculated between the date of diagnosis and the date of death, date last known to be alive, or date of the study cut-off (31 December 2018). Variables significant in univariate analysis were included in a multivariate analysis. The Kaplan-Meier method was used to calculate overall survival (OS), and Cox regression model was used to identify predictors of survival. Statistical analyses were performed using JMP version 14.0. Results: 10,988 patients with PV, 9,146 with ET, and 4,022 with PMF were identified in SEER. The median age of diagnosis (interquartile range [IQR]) was 65 years (IQR 54-76), 67 years (IQR 54-77), and 69 years (IQR 60-78) for PV, ET, and PMF respectively. Overall incidence rates (cases/100,000) were 0.86 for PV, 0.72 for ET, and 0.30 for PMF. With a median follow up (in years, 95% confidence interval [CI]) of 7.6 (7.4-7.8), 7.9 (7.8-8.2), and 7.25 (7.0-7.5), the median OS was 11.4 (11.2-11.7), 11.75 (11.3-12.0), and 3.5 (3.3-3.7), for PV, ET, and PMF respectively. RS was better than expected survival for PV and ET, while less than expected survival for PMF (Figure 1). 3853 of PV patients died (35.1%) by the end of the study period, with 4.1% and 34.1% of deaths from PV-related and cardiovascular disease respectively (Table 1). 3142 of ET patients died (34.4%), with 7.2% and 32.2% of deaths from ET-related and cardiovascular disease respectively. 2578 patients with MF died (64.1%), with 13.2%, and 51.9% of deaths from PMF-related and other malignancies respectively. 106 patients (1.0%) with PV, 135 patients (1.5%) with ET, and 127 patients (3.2%) with PMF transformed to AML. Median time to transformation was 4.8, 6.3, and 2.3 years for PV, ET, and PMF respectively. Factors indicating inferior OS on multivariate analysis (Table 2) included age ≥ 65, female sex, and year of diagnosis for PV, age ≥ 65, male sex, and year of diagnosis for ET, and age ≥ 65, and male sex for PMF. Conclusion: Incidence rates for PV, ET, and PMF were similar to previous reports. RS was better than expected survival for PV and ET, while less than expected survival for PMF. The majority of deaths in ET and PV occurred from cardiovascular disease; a finding likely related to these MPNs. Patients with PMF were more likely to die from their disease or a subsequent malignancy. Transformation to AML occurred less frequently than prior large case series, noting a limitation in the current study. Patients with PMF were more likely to transform to AML with a shorter time interval. Older age was associated with worse OS in all patients. Male sex was predictive of worse survival for ET and PMF, while female sex was associated with worse survival in PV. Over the years, survival has improved for PV and remained essentially unchanged for ET and PMF. Figure Disclosures Shah: Dren Bio: Consultancy.
The Role of Staging Evaluation at Initial Diagnosis of Adult Patients with Clinically Isolated Pulmonary Langerhans Cell Histiocytosis
Ruan, Gordon , Abeykoon, Jithma P. , Scheckel, Caleb , Bennani, Nabila Nora, Hazim, Antonious , Ravindran, Aishwarya , Vassallo, Robert , Ryu, Jay H. , Tobin, W. Oliver , Koster, Matthew J. , Rech, Karen L. , Young, Jason R. , Shah, Meera , Goyal, Gaurav , Go, Ronald S.

Mayo Clinic

Blood | February 7, 2021 | Volume: 136 | Issue: Supplement 1 | Pages: 45-45

10.1182/blood-2020-136861 Get It

Background: Langerhans cell histiocytosis (LCH) is the most common histiocytic disorder that is now recognized as a neoplasm by the World Health Organization. It is generally classified based on the site and extent of disease involvement (single system or multisystem). Pulmonary LCH (pLCH), an uncommon interstitial lung disease associated with smoking, often presents as isolated pulmonary disease. It is unclear whether patients with clinically isolated pLCH have extra-pulmonary lesions at diagnosis or during the course of their disease. The role of [18F] fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET-CT) in the staging of pLCH remains unclear. Our study aims to better characterize the utility of radiographic staging studies at time of diagnosis and prevalence of extrapulmonary disease at follow up in pLCH. Methods: We conducted a retrospective study of patients presenting with clinical findings consistent with isolated pLCH seen at the Mayo Clinic from January 2000 to January 2020. All patients had a diagnosis of pLCH determined by chest imaging studies [computed tomography (CT) or high-resolution CT (HRCT)] or by histopathologic findings from surgical or transbronchial lung biopsy. Histopathologic findings for the diagnosis of pLCH required the presence of Langerhans cells (S100+/CD1a+/Langerin+). Patients were excluded if they had clinically apparent extra-pulmonary organ involvement at the time of diagnosis. BRAF V600E mutation was determined by immunohistochemistry (IHC) or cell-free DNA (cfDNA). Staging was defined as FDG-PET-CT or whole body CT imaging obtained within 3 months of diagnosis of pLCH. Extra-pulmonary LCH involvement was determined by imaging characteristics or by histopathologic findings. Descriptive statistics and overall survival (OS) were analyzed with JMP software, version 14 (SAS Institute Inc., Cary, NC). Results: A total of 112 patients with clinically isolated pLCH were identified. The median age at diagnosis was 45 years (range 21-73), and 48 (43%) were male. The majority (n=110, 99%) were former or current smokers with a median pack year of 25 (range 1-57). Three (3%) patients were noted to have occupational industrial exposure. Nine patients had a history of another cancer prior to their diagnosis and staging of pLCH [lung (n=4), breast (n=2), neuroendocrine (n=2), thyroid (n=1)]. Presenting symptoms included dyspnea on exertion 49 (44%), cough 18 (16%), chest pain 14 (13%), and 29 (28%) were incidentally discovered on imaging studies. On HRCT, the following characteristics were observed: 42 (38%) cystic, 32 (29%) cystic and nodular, 37 (33%) nodular, 1 (&lt;1%) ground glass opacities. Seventy (63%) patients had lung biopsy confirmation, of which 11 (16%) patients underwent BRAF V600Emutation testing (7 by IHC, 4 by cfDNA). Six (55%) of these 11 patients were positive for BRAF V600E mutation. 34 (30%) patients underwent radiographic staging studies within 3 months of diagnosis of pLCH (25 FDG-PET-CT and 9 whole-body CT), and none of these imaging studies showed evidence of extra-pulmonary disease. Of the patients who had at least one year of follow-up (n=52), one (2%) developed extra-pulmonary disease. This patient did not undergo initial staging studies, developed headaches and was found to have a large calvarial lytic lesion within 2 months of pLCH diagnosis (BRAF V600E+). Among those who did not undergo staging at diagnosis (n=78), long term (&gt;5 years) follow up data were available for 23 (29%), and none developed extra-pulmonary disease as determined by clinical notes or imaging studies. No patient had evidence of new extra-pulmonary involvement or second malignancy at the time of last known follow-up. After a median follow-up duration of 2.4 years (95% CI: 1.5-3.6, range: 0.1-17) ten (9%) patients died, of which 5 died of pLCH related complications. The median OS for entire cohort was 15 years (95% CI 9.1-not reached, Figure 1). Conclusion: Our study shows that adult patients with clinically isolated pLCH rarely present with extra-pulmonary manifestations at diagnosis or at follow up. These findings suggest a limited role of routine radiographic staging studies in pLCH unless clinically indicated. Studies on longer follow up of this cohort would provide further insights into the natural history of pLCH and are underway. Disclosures Bennani: Purdue Pharma: Other: Advisory Board; Verastem: Other: Advisory Board; Kite/Gilead: Research Funding; Affimed: Research Funding. Shah:Dren Bio: Consultancy.
Proficiency Testing for Laboratories Performing Fluorescence In Situ Hybridization With Chromosome-Specific DNA Probes
Mascarello, James T., Brothman, Arthur R., Davison, Keri, Dewald, Gordon W., Herrman, Marille, McCandless, Danette, Park, Jonathan P., Persons, Diane L., Rao, Kathleen W., Schneider, Nancy R., Vance, Gail H. , Cooley, Linda D.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 29, 2021 | Volume: 126 | Issue: 12 | Pages: 1458-1462

10.5858/2002-126-1458-ptflpf | PMID 12456204 Get It

Abstract Objective.—To assess laboratory performance, use, and limitations in the joint College of American Pathologists and American College of Medical Genetics proficiency testing program for laboratories performing cytogenetic tests based on fluorescence in situ hybridization (FISH). Data Sources.—Eight proficiency surveys dealing with FISH detection of microdeletions or microduplications, aneuploidy in interphase cells, gene amplification, and neoplasm-specific translocations. Participating laboratories used their own DNA probes (commercial or home-brew), hybridization methods, and analytic criteria to answer clinical questions about cases represented by slides included in the survey materials. They also described their test results according to the International System for Human Cytogenetic Nomenclature (ISCN) and answered supplementary questions relating to their experience with the subject test systems. Data Extraction.—In addition to evaluating diagnostic accuracy, we evaluated survey use, laboratory experience, variation in methodologic approach, and the practicality of using ISCN nomenclature for describing test results. Synthesis and Conclusions.—With the exception of one challenge, at least 80% of the participants reached the correct diagnostic conclusion. In the sole exception, there was still a consensus of 91.7% of participants with the same (albeit erroneous) diagnostic conclusion. The overall outstanding performance of participating laboratories clearly shows the reliability of current FISH methods. Despite the fact that a large number of laboratories reported little or no experience with the specific test systems, the overwhelming majority performed very well. This result shows that the program's strategy of targeting classes of abnormalities (vs a single abnormality associated with a specific disease) did not put at a disadvantage participants who did not routinely perform all of the potential tests in the class. The extraordinary variation in ISCN descriptions submitted by participants showed that the existing system for human cytogenetic nomenclature is not suitable for facile communication of FISH test results.
Extensive Analysis of Mosaicism in a Case of Turner Syndrome
Park, Jonathan P., Brothman, Arthur R., Cooley, Linda D. , Dewald, Gordon W., Lundquist, Kurt, Palmer, Catherine G., Patil, Shivanand R., Rao, Kathleen W., Saikevych, Irene A., Schneider, Nancy R., Vance, Gail H. , Butler, Merlin G.

Mayo Clinic

Archives of Pathology and Laboratory Medicine | January 28, 2021 | Volume: 123 | Issue: 5 | Pages: 381-385

10.5858/1999-123-0381-eaomia | PMID 10235494 Get It

Abstract Objective. —To assemble and interpret karyotype data provided as part of the College of American Pathologists/American College of Medical Genetics Cytogenetics Proficiency Testing Program. Data Sources, Extraction, and Synthesis. —The Cytogenetics Resource Committee requested data on all cells analyzed in a 1994 whole-blood specimen challenge. In that study, 287 participating laboratories analyzed a total of 14297 cells derived from a sample drawn from an adult donor with Turner syndrome. This individual had previously been found to have mosaicism, including cell lines with X structural anomalies along with monosomy X, making this an excellent challenge for a multicenter cytogenetic survey. Results and Conclusions. —Analysis of the data from this extensive study revealed mosaicism of up to 10 different sex chromosome complements involving the X chromosome with and without a small ring X or a derivative X chromosome. In the routine cytogenetic analysis performed by the participating laboratories, cell lines observed, in decreasing order of prevalence, included 45,X (n = 8357 cells), 46,X,r(X) (n = 3597), 46,X,der( X )t( X ;X) (n = 2237), 46,XX (n = 93), 47,X,r(X),r(X) (n = 5), 47,X,der( X )t( X ;X),der( X )t( X ;X) (n = 3), 47,XX,r(X) (n = 2), and one observation each of 47,XX,der( X )t( X ;X), 47,X,der( X )t( X ;X),r(X), and 47,XXX. Our molecular cytogenetic data, as well as detailed analysis of G-banded chromosomes, suggest the nomenclature for these 2 abnormal X chromosomes as r(X)(p11.3q21.3) and der( X )t( X ;X)(p11.3;q21.3), and we discuss models for the concomitant formation of these 2 entities. Both the degree of analysis and the extensive mosaicism that was discovered in this study are exceptional, and similar reported cases as well as possible mechanisms for the observed X chromosome instability are reviewed.